Current:Home > InvestGM to retreat from robotaxis and stop funding its Cruise autonomous vehicle unit -WealthX
GM to retreat from robotaxis and stop funding its Cruise autonomous vehicle unit
View
Date:2025-04-13 18:59:05
DETROIT (AP) — General Motors said Tuesday it will retreat from the robotaxi business and stop funding its money-losing Cruise autonomous vehicle unit.
Instead the Detroit automaker will focus on development of partially automated driver-assist systems like its Super Cruise, which allows drivers to take their hands off the steering wheel.
GM said it would get out of robotaxis “given the considerable time and resources that would be needed to scale the business, along with an increasingly competitive robotaxi market.”
The company said it will combine Cruise’s technical team with its own to work on advanced systems to assist drivers.
GM bought Cruise automation in 2016 for at least $1 billion with high hopes of developing a profitable fleet of robotaxis.
Over the years GM invested billions in the subsidiary and eventually bought 90% of the company from investors.
GM even announced plans for Cruise to generate $1 billion in annual revenue by 2025, but it scaled back spending on the company after one of its autonomous Chevrolet Bolts dragged a San Francisco pedestrian who was hit by another vehicle in 2023.
The California Public Utilities Commission alleged Cruise then covered up detailsof the crash for more than two weeks.
The incident resulted in Cruise’s license to operate its driverless fleet in California being suspended by regulatorsand triggered a purge of its leadership— in addition to layoffs that jettisoned about a quarter of its workforce.
Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.
veryGood! (8724)
Related
- IRS recovers $4.7 billion in back taxes and braces for cuts with Trump and GOP in power
- Ozone, Mercury, Ash, CO2: Regulations Take on Coal’s Dirty Underside
- How Kelly Ripa and Mark Consuelos Celebrated Their 27th Anniversary
- The new U.S. monkeypox vaccine strategy offers more doses — and uncertainty
- DoorDash steps up driver ID checks after traffic safety complaints
- Trump-appointed federal judge rules Tennessee law restricting drag shows is unconstitutional
- Ice Loss and the Polar Vortex: How a Warming Arctic Fuels Cold Snaps
- Coronavirus FAQ: Does a faint line on a self-test mean I'm barely contagious?
- Trump issues order to ban transgender troops from serving openly in the military
- At 988 call centers, crisis counselors offer empathy — and juggle limited resources
Ranking
- The city of Chicago is ordered to pay nearly $80M for a police chase that killed a 10
- Over half of people infected with the omicron variant didn't know it, a study finds
- Vanderpump Rules' Explosive Teaser Shows Tom Sandoval & Raquel Leviss Together Again
- Teresa Giudice Says She's Praying Every Day for Ex Joe Giudice's Return to the U.S.
- Can Bill Belichick turn North Carolina into a winner? At 72, he's chasing one last high
- Teresa Giudice Says She's Praying Every Day for Ex Joe Giudice's Return to the U.S.
- Billie Lourd Calls Out Carrie Fisher’s Siblings for Public “Attacks” in Rare Statement
- Coronavirus FAQ: Does a faint line on a self-test mean I'm barely contagious?
Recommendation
The company planning a successor to Concorde makes its first supersonic test
Rihanna's Makeup Artist Reveals the Most Useful Hack to Keep Red Lipstick From Smearing
Highlighting the Allure of Synfuels, Exxon Played Down the Climate Risks
Michigan's abortion ban is blocked for now
Civic engagement nonprofits say democracy needs support in between big elections. Do funders agree?
Water Source for Alberta Tar Sands Drilling Could Run Dry
Rihanna's Makeup Artist Reveals the Most Useful Hack to Keep Red Lipstick From Smearing
The new U.S. monkeypox vaccine strategy offers more doses — and uncertainty